New Hampshire Senate Panel Amends House-Passed Marijuana Legalization Bill, Sending It To Final Floor Vote
Change To Minnesota’s Marijuana Law Makes All Military Veterans Eligible For Social Equity Status
Louisiana Medical Marijuana Farming Duties Would Transfer From Universities To Private Firms Under Bill On Governor’s Desk
California Lawmakers Approve Bill To Legalize Marijuana Cafes, Months After Governor’s Veto Of Earlier Measure
Feds Begin Accepting Marijuana Rescheduling Comments, With Key Reform Groups Previewing How They Plan To Influence The Process
Marijuana Use Linked To Increase In Light Physical Activity, Study Challenging ‘Lazy Stoner’ Stereotype Finds
Psychedelic Mushrooms Won’t Make You Believe In God, But They Might Make You Think Robots Are Conscious, Study Finds
Cannabis Can Help Treat Female Orgasmic Disorder, Study Finds As Ohio Officials Consider Adding It As Qualifying Condition
Interaction Of Marijuana Terpenes And Cannabinoids Offers ‘Hope’ For ‘Novel’ Treatments, Study Says
Frequent Marijuana Use Doesn’t Make People Less Motivated Or Cause Paranoia, Study Finds
Brands And Advocacy Groups—From ACLU To KFC—Launch 4/20 Promotions To Mark The Marijuana Holiday
Former Minnesota Gov. Jesse Ventura Promotes New Cannabis Brand Ahead Of 4/20 That He’d ‘Offer To You’ On Governor’s Mansion Visit
Colorado Amendment Addresses Concerns On Banning Social Media Marijuana Posts, But Questions On Psychedelics And Other Drugs Remain
Former Minnesota Governor Jesse Ventura Launches His Own Cannabis Brand, Fulfilling A ‘Lifelong Dream’
Marijuana Rolling Paper Company Seeks Content Creator To ‘Get Paid To Smoke Weed’ For $70,420 Salary
States Have Generated Over $20 Billion In Marijuana Tax Revenue Since First Markets Opened, New Report Finds
Arkansas Medical Marijuana Dispensary Gets License Revoked Over Alleged Violations
New Jersey Set A New Marijuana Sales Record Last Quarter, With Regulators Touting ‘Historical Highs’ On 4/20 Weekend
Massachusetts Saw Record-Breaking Marijuana Sales On 4/20, Pushing State Across $6 Billion Mark For Recreational Purchases
Legal Marijuana Purchases In Michigan Spiked In March, Reaching A New Record High
New Hampshire Senate Panel Amends House-Passed Marijuana Legalization Bill, Sending It To Final Floor Vote
DeSantis Will Respect Florida Voters’ Legalization Decision At The Ballot Even As State Officials Urge Opposition, Marijuana Company CEO Says
Democratic Senator Who Voted Against Marijuana Banking Bill Voices Continued ‘Concern’ With Lack Of Criminal Justice Reform
New Hampshire Senate Approves Marijuana Legalization Bill After Adopting Changes To House-Passed Version
Biden Makes Historic Marijuana Rescheduling Announcement, Applauding ‘Monumental’ Move To Reverse ‘Longstanding Inequities’
DOJ weighs cannabis economic impact of rescheduling (Newsletter: May 21, 2024)
Biden campaign’s cannabis criticism for Trump (Newsletter: May 20, 2024)
Biden announces cannabis rescheduling (Newsletter: May 17, 2024)
Hemp & marijuana biz disagree on Farm Bill (Newsletter: May 16, 2024)
Congress considers ending cannabis tests for military recruits (Newsletter: May 15, 2024)
Published
on
By
Spiritual health practitioners “bring unique and specific expertise to psychedelic-assisted therapy,” researchers at Emory University concluded in a recently published study, noting that therapy teams could benefit from including the professionals in their work.
“Psychedelic dosing often produces highly impactful, and sometimes challenging, experiences with pronounced effects on spirituality, worldview, and metaphysical perspectives,” wrote authors of the report, published in the journal PLOS ONE. Spiritual health practitioners (SHPs) “may have unique, and uniquely valuable, contributions to support the participant’s wellbeing and helping them benefit” from psychedelic-assisted therapy (PAT).
As the paper explains, SHPs include those who traditionally served “as chaplains or military settings to provide religiously-based pastoral care to those who share their denomination,” though the term has also come to mean “providing spiritual support for people of any or no religious affiliation.”
Despite that broad description, the work typically requires significant training. Qualifying as a board certified chaplain, for example, “involves completion of 1600 clinical and educational hours, 2000 hours of additional clinical practice, endorsement from a religious/spiritual community, submission of four position papers, and committee approval based on demonstration of 31 competencies”—usually after years of seminary and theological training.
Authors noted the long history of religious and spiritual use of psychedelics, especially in some indigenous traditions, which has often intertwined with medical and therapeutic use.
“A core professional role of SHPs is to address spiritual needs, which are defined as concerns deemed sacred by a person within their life and may or may not include religious components,” they explained. “Given the prevalence and importance of spiritual content in psychedelic experiences, and its potential as a mediator of therapeutic effects, SHPs are uniquely positioned to contribute to PAT in ways likely to optimize its therapeutic benefit.”
The report is the product of the eight-author research team’s interviews with 15 spiritual health practitioners with experience facilitating psychedelic therapy in legal settings. Authors then analyzed “their contributions, application of expertise and professional background, and roles in administering these therapies.” The team said the study is notable in part because the roles and competencies of SHPs in PAT “have not been described in research.”
“As physicians are competent to respond to psychological concerns, and mental health practitioners are competent to respond to psychological concerns,” their report concludes, “SHPs are competent to respond to spiritual concerns of the psychedelic experience.”
And as more patients who are suffering continue to turn to psychedelic-assisted therapy (PAT), it reasons, “treatment teams will have the opportunity to respond to these needs in a holistic manner, taking into account the full dimension of the human experience, inclusive of spiritual dynamics through inclusion of SHPs on their interdisciplinary teams.”
Specifically, researchers said, their qualitative analysis found seven themes that illustrated SHPs’ potential usefulness in PAT, which they divided into unique versus general contributions.
Unique contributions to a therapy team included competency to work with spiritual material, awareness of power dynamics, familiarity with non-ordinary states of consciousness, holding space and offering a counterbalance to more traditional Western biomedical perspectives. General contributions, meanwhile, included fluency with generalizable “therapeutic repertoire” as well as adding to interdisciplinary collaboration.
Though the findings suggest that the incorporation of spiritual health practitioners could benefit some participants in psychedelic-assisted therapy, the study acknowledges it has some limitations. Most notably, because the survey responses from SHPs were qualitative and retrospective, the study “cannot address questions of causality or speak to the effectiveness of the therapeutic approaches used by the SHPs.”
To support adequate sampling, the report added, the study also relied on the interviewers’ professional network, which “may have biased inclusion of professionals who share views similar to those held by the [interviewer], and may have biased responses toward those aligned with those views.”
The study also relied solely on interviews with SHPs practicing in legal contexts, which the report says “may have excluded perspectives of of SHPs with experience in community based (i.e., “underground”) contexts.”
“In community-based settings, SHPs or spiritual guides have been providing psychedelic-assisted care for decades, sometimes building from ancient practices in indigenous communities, suggesting a wealth of knowledge that may inform the conduct of PAT in medical settings,” authors noted. “In the field at large, there has been limited research addressing the experience of Black, Indigenous and people of color with PAT. This limitation characterizes the present research about SHPs providing PAT. In our study SHP participants were predominantly white, and the study included limited perspectives of those who identified as Black, Indigenous, and people of color.”
Limitations notwithstanding, interviews with the SHPs demonstrated that the care providers “have emerged as essential members of the interdisciplinary care team offering bedside care to patients and their care partners,” the study found.
The findings come as support builds for broader access to psychedelic-assisted therapy, including among the nation’s military veterans. Another recent study found that strong majorities of active duty military, veterans and their family members support allowing U.S. Department of Veterans Affairs (VA) doctors to recommend medical marijuana and psychedelics to patients if they believe it would provide a benefit.
Currently, there are no Food and Drug Administration (FDA)-approved psychedelic therapies—but that could change in 2024.
The FDA granted priority review to a new drug application for MDMA-assisted therapy following the completion of multiple clinical trials that supported the drug’s effectiveness as a therapeutic for moderate and severe PTSD. If the application is approved, the Drug Enforcement Administration (DEA) would then need to reschedule MDMA accordingly. It would become the first psychedelic in history to be approved as a pharmaceutical.
The federal agency has already designated MDMA and psilocybin as breakthrough therapies for the treatment of post-traumatic stress disorder (PTSD) and severe depression, respectively.
The Multidisciplinary Association for Psychedelic Studies (MAPS) published the results of a recent Phase 3 trial in the journal Nature in September, finding that MDMA “significantly attenuated PTSD symptomology versus placebo with therapy.”
Meanwhile, a separate study, by researchers at New York University’s Langone Center for Psychedelic Medicine and the Centre for Psychedelic Research at Imperial College London recently found that pairing MDMA with either psilocybin or LSD helped people overcome the “challenging experiences” associated with use of psilocybin or LSD alone.
In 2022, the Biden administration said it was “actively exploring” the possibility of creating a federal task force to investigate the therapeutic potential of psilocybin, MDMA and others ahead of the anticipated approval of the substances for prescription use.
In California, meanwhile, Gov. Gavin Newsom (D) signed a bill in October that would allow doctors to immediately start prescribing certain currently illicit drugs like psilocybin and MDMA if they’re federally rescheduled.
Last year, Australia legalized MDMA and psilocybin for use by prescription.
Maryland Senate Approves Psychedelics Task Force Bill To Study ‘Equitable And Affordable’ Access To Psilocybin And DMT
Legalizing Marijuana For Adults Does Not Drive Increases In Youth Use, New Federally Funded Study Finds
Psychedelic Use Linked To ‘Lower Rates Of Psychotic Symptoms’ In Adolescents, Study Published By American Medical Association Finds
Ben Adlin, a senior editor at Marijuana Moment, has been covering cannabis and other drug policy issues professionally since 2011. He was previously a senior news editor at Leafly, an associate editor at the Los Angeles Daily Journal and a Coro Fellow in Public Affairs. He lives in Washington State.
All the cannabis news you need, all in one place. Copyright © 2017-2024 Marijuana Moment LLC ® and Tom Angell
Spiritual Health Practitioners Bring 'Unique, And Uniquely Valuable' Expertise To Psychedelic-Assisted Therapy, Study … – Marijuana Moment
